Aerie shares shoot up as in­ves­ti­ga­tors take an­oth­er big step to an NDA with 2nd pos­i­tive glau­co­ma PhI­II

Aerie Phar­ma­ceu­ti­cals is now two for two on its piv­otal Phase III stud­ies for Ro­cla­tan, a com­bo drug that com­bines the gener­ic la­tanoprost to its in-house drug Rho­pres­sa.

In­ves­ti­ga­tors re­port­ed top line da­ta to­day, say­ing that the com­bo beat each of the two drugs sep­a­rate­ly in low­er­ing in­traoc­u­lar pres­sure, the key gauge for suc­cess here.

Once again, Aerie shares $AERI took off on the news, spik­ing more than 30% Thurs­day as in­vestors pon­dered the im­pli­ca­tions. The biotech promised to file for an ap­proval in the first half of 2018, pro­vid­ed an on­go­ing safe­ty study ends suc­cess­ful­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.